Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 505-513 , July 2009

Development of high-specific-activity 68Ga-labeled DOTA-rhenium-cyclized α-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors

  • Melchor V. Cantorias

      Affiliations

    • University of Missouri Research Reactor Center (MURR), Columbia, MO 65211, USA
    • ,
  • Said D. Figueroa

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65212, USA
    • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Thomas P. Quinn

      Affiliations

    • Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
    • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • John R. Lever

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65212, USA
    • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Timothy J. Hoffman

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65212, USA
    • ,
  • Lisa D. Watkinson

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65212, USA
    • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Terry L. Carmack

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65212, USA
    • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Cathy S. Cutler

      Affiliations

    • University of Missouri Research Reactor Center (MURR), Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 573 882 5211; fax: +1 573 882 6671.

Received 30 October 2008 ,Revised 26 January 2009 ,Accepted 31 January 2009.

References 

  1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and targeted therapy. Nature. 2007;445:851–857
  2. Cancer facts and figures. Atlanta (Ga): American Cancer Society; 2007;http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf[Accessed August 16, 2007]
  3. Dadachova E, Casadevall A. Renaissance of targeting molecules for melanoma. Cancer Biother Radio. 2006;21:545–552
  4. Rampen FH, Casparie-van Velsen JI, van Huystee BE, Kiemeney LA, Schouten LJ. False-negative findings in skin cancer and melanoma screening. J Am Acad Dermatol. 1995;33:59–63
  5. Tatro JB, Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology. 1987;121:1900–1907
  6. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352–6358
  7. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for alpha-melanocyte-stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int J Cancer. 1988;41:248–255
  8. Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp Dermatol. 1996;5:325–333
  9. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP. Modification of the structure of a metallopeptide: synthesis and biological evaluation of 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem. 2002;45:3048–3056
  10. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706
  11. Bagutti C, Stolz B, Albert R, Bruns C, Pless J, Eberle AN. 111In-DTPA-labeled analogues for alpha-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int J Cancer. 1994;58:749–750
  12. Bard DR, Knight CG, Page-Thomas DP. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer. 1990;62:919–922
  13. Wraight EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha-melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol. 1992;65:112–118
  14. Morgensen CE, Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clinic Lab Invest. 1977;37:477–486
  15. Bass LA, Lanahan MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, et al. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide. Bioconjug Chem. 1998;9:192–200
  16. Franano FN, Edwards WB, Welch MJ, Duncan JR. Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-ɛ-lysine as the primary metabolic and excretory product. Nucl Med Biol. 1994;21:1023–1034
  17. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev. 1988;68:911–1007
  18. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med. 1993;34:1728–1738
  19. Maack T, Johnson V, Kan ST, Figueiredo J, Sigulem D. Renal, filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int. 1979;16:251–270
  20. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, et al. Identification of metabolites of 111In-diethylene-triaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995;55(Suppl):5714s–5720s
  21. Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med. 2005;46:887–895
  22. Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-labeled alpha-melanocyte-stimulating hormone for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18:765–772
  23. Chen JQ, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mtechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  24. Miao Y, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002;101:480–487
  25. Giblin MF, Wang NN, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998;95:12814–12818
  26. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res. 2005;11:5616–5621
  27. Miao Y, Shelton T, Quinn TP. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone in a murine melanoma-bearing mouse model. Cancer Biother Radio. 2007;22:333–340
  28. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis LS. 68Ga-labeled DOTA-rhenium cyclized α-MSH peptide analog: a potential radiopharmaceutical for PET imaging of malignant melanoma. J Nucl Med. 2007;48(Suppl 2):21P;[Abstract]
  29. Froidevaux S, Calame-Christe M, Schumacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116–123
  30. Colombetti LG, Colombetti LG. Study of 68Ga–EDTA complex. Possible applications in nuclear medicine. Acta Isotopica. 1971;11(1):17
  31. Friedlander G, Kennedy JW, Macias ES, Miller JM. Nuclear and radiochemistry. 3rd ed.. New York: John Wiley and Sons; 1981;
  32. Cherry SR, Sorenson , Phelps ME. Physics in nuclear medicine. 3rd ed.. Philadelphia: Elsevier; 2003;
  33. Maecke HR, Andre JP. 68Ga-PET radiopharmacy: a generator-based alternative to 18F- radiopharmacy. Ernst Schering Res Found Workshop. 2007;62(PET Chemistry):215–242
  34. Cutler CS, Giron CG, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, et al. Evaluation of gallium-68 Tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. Nucl Med Biol. 1999;26:305–316
  35. Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554–560
  36. Stone-Elander S, Elander N. Microwave applications in radiolabeling with short-lived positron-emitting radionuclides. J Label Compd Radiopharm. 2002;45:715–746
  37. Hwang DR, Moerlein SM, Lang L, Welch MJ. Application of microwave technology to the synthesis of short-lived radiopharmaceuticals. J Chem Soc (Chem Commun). 1987;1799–1801
  38. Velikyan I, Beyer GJ, Bergstroem-Pettermann E, Johansen P, Bergstroem M, Laangstroem B. The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. Nucl Med Biol. 2008;35:529–536
  39. Chen JQ, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, et al. Evaluation of an 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med. 2001;42:1847–1855
  40. Dymov AM, Savostin AP. Analytical chemistry of gallium. Ann Arbor: Ann Arbor Science Publishers; 1970;
  41. Anderson CJ, Welch MJ. Gallium. In:  Seiler HG, et al. editor. Handbook on metals in clinical and analytical chemistry. New York: Marcel Dekker, Inc.; 1994;p. 371–380
  42. Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bionconjug Chem. 2008;19:569–573
  43. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vāvere AL, et al. Ga-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945–953
  44. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of peptide analogue of α-MSH. J Med Chem. 2005;48:2985–2992
  45. Sharma SD, Jiang J, Hadley ME, Bentley DL, Hruby VJ. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropic receptors. Proc Natl Acad Sci U S A. 1996;93:13715–13720
  46. Eberle AN, Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit. 2003;16:248–254
  47. Kappe CO, Dallinger D. Microwave-assisted synthesis in water as solvent. Chem Rev. 2007;107:2563–2591
  48. Cantorias MV, Quinn TP, Cutler CS. Synthesis of high specific activity melanoma targeting agents. J Nucl Med. 2007;48(Suppl 2):315P;[Abstract]
  49. Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev. 2008;34:13–26
  50. Miao Y, Fisher DR, Quinn TP. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol. 2006;33:723–733
  51. Chen JQ, Wang N, Jurisson SS, Quinn TP. Biodistribution properties of linear and cyclic 99mTc-labeled α-melanotropin peptides. In:  Nicolini M,  Mazzi U editor. Technetium, rhenium, and other metals in chemistry and nuclear medicine. Padova, Italy: SG Editorial; 1998;p. 457–463
  52. Carrasquillo JA, Lang L, Whatley M, Herscovitch P, Wang QC, Pastan I, et al. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. Cancer Res. 1998;58:2612–2617

PII: S0969-8051(09)00043-2

doi: 10.1016/j.nucmedbio.2009.01.017

Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 505-513 , July 2009

Article Tools

* Image Usage & Resolution